MC
IRD

Moors & Cabot’s Opus Genetics IRD Stock Holding History

Moors & Cabot’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-23
Closed -$7K – 552
2015
Q1 		$7K Sell
23
-15
-39% -$5.45K ﹤0.01% 511
2014
Q4 		$12K Sell
38
-14
-27% -$4.83K ﹤0.01% 504
2014
Q3 		$19K Hold
52
– – ﹤0.01% 533
2014
Q2 		$22K Buy
52
+29
+126% +$13.2K ﹤0.01% 531
2014
Q1 		$12K Buy
+23
New +$12.4K ﹤0.01% 378

Other funds holding IRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
HVIA
Hudson Valley Investment Advisors Goshen, New York $823M AUM 31.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Moors & Cabot's IRD Position: Q2 2015 in Review

Moors & Cabot sold out of Opus Genetics (IRD) in Q2 2015, closing a stake of 23 shares — an estimated $7K sold.

Moors & Cabot first reported a position in IRD in Q1 2014 and held it in 5 quarters. The position peaked at $22K in Q2 2014. 35 funds tracked by Wall St. Rank hold IRD as of Q2 2015.

  • Moors & Cabot reported no remaining Opus Genetics position as of Q2 2015 after selling out during the quarter.
  • Moors & Cabot sold 23 Opus Genetics shares in Q2 2015, an estimated $7K.
  • Moors & Cabot first reported a position in Opus Genetics in Q1 2014 and held it in 5 quarters.
  • Moors & Cabot's Opus Genetics position peaked at $22K in Q2 2014.
  • 35 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2015.

Based on Moors & Cabot's 13F filing for Q2 2015, filed 17 Aug 2015.